Clinical Trial Update: Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating weekly paclitaxel combined with low-dose estramustine and carboplatin in hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Estramustine (estramustine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED